Re: Does anyone else see this issue between Moore and TPL as a positive?

Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Reply New Message

Prev Message Back To Forum Threaded View Next Message

milestone

Rank: President [?]

Points: 18650 [?]

Votes: 158 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Does anyone else see this issue between Moore and TPL as a positive?

in response to

Does anyone else see this issue between Moore and TPL as a positive?

srandl

posted on Apr 05, 2009 09:10AM

Sorry to disagree with you but I don't see the need for PTSC to employ Moore.

PTSC is moving away from licensing the MMP Portfolio as a source for future revenues/growth. Moore's input to the patents is as important to him as anyone, if not more so. Without validated patents there is no income stream.

It would appear that Jennifer Harris-Lohse holds the key to what did or did not transpire, ITEM 9, REEL: 014083 FRAME: 0994

http://patentabilityenterprises.com/...

http://www.colorforth.com/assignment...

One fact being overlooked in the debate to dismiss TPL/Alliacense is the current expiry of the patents.

How long and at what cost would it take to bring a new team up to date on the reverse-engineered chips alone? I don't see buying the results from TPL as a viable option as the price demanded would probably be close to the anticipated license fee revenue.

I also expressed concerns about the agreement when the P-Newco details were made available and nothing has changed since then. In my very humble opinion, TPL remains an integral part of PTSC's near-term revenues, and also over the course of the patents' validity. Mr Moore's action may have loosened the stranglehold but only time will tell.